|
ASHI Governance
Standards for Histocompatibility Testing Section K - Marrow Transplantation K1.000
Histocompatibility Testing K1.100
HLA-A,-B,-C,-DR and -DQ typing of all available first degree relatives
should be done to establish inheritance of haplotypes. K1.120
HLA typing for HLA identical siblings (and other first degree
relatives) must include adequate testing to definitely establish HLA
identity. Molecular HLA typing or augmented testing (e.g. MLC, T cell
precursor frequency) should be performed as appropriate for the
transplant protocol and optimal donor selection. K1.130
HLA typing for potential donors who are not first degree relatives
must include molecular typing for Class II alleles at a level that is
appropriate for the transplant protocol and optimal donor selection.
Augmented testing (e.g. molecular typing for Class I HLA,
bidirectional MLC, T cell precursor frequency) should be performed as
appropriate for the transplant protocol and optimal donor selection. K2.000
Forward and reverse lymphocytotoxicity and granulocytotoxicity
crossmatch tests (patient serum, donor cells and donor serum, patient
cells) may be advisable. K3.000
When the patient has aplastic anemia, every effort should be made to
complete tests as rapidly as possible to minimize the number of
pretransplant blood transfusions. K4.000
Unrelated donors. K4.100
The donor should give his informed consent before blood is taken for
typing and before the donor is placed on a list of donors available to
be called. K4.200
Donor records should be maintained so that donors can be rapidly
retrieved according to HLA type. K4.300 Laboratories should have a mechanism in place for resolving any tissue typing discrepancies that may occur between laboratories. |
Board
of Directors
|
